Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Organogenesis Holdings Leads These 3 US Penny Stocks

In This Article:

As the U.S. stock market navigates mixed signals from earnings reports and economic data, investors remain vigilant in their search for promising opportunities. Penny stocks, a term that may seem outdated yet still relevant, offer potential growth avenues often found in smaller or newer companies with solid financial foundations. In this article, we will explore several penny stocks that demonstrate financial strength and long-term potential, providing a glimpse into under-the-radar opportunities for discerning investors.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$93.03M

★★★★★★

BAB (OTCPK:BABB)

$0.8999

$6.54M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.40

$9.63M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.56

$1.91B

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.3052

$11.04M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.57

$50.16M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.78

$43.03M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.14

$20.75M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9143

$81.09M

★★★★★☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Organogenesis Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of approximately $363.35 million.

Operations: The company's revenue is primarily derived from its regenerative medicine segment, which generated $455.04 million.

Market Cap: $363.35M

Organogenesis Holdings Inc. has demonstrated financial resilience with short-term assets of US$238.5 million exceeding both short and long-term liabilities, and its interest payments are well-covered by EBIT. Despite being unprofitable, the company has reduced losses over the past five years and forecasts significant earnings growth. Recent strategic moves include a share repurchase program funded by preferred stock sales, expansion plans for a new biomanufacturing facility in Rhode Island, and positive interim results from a Phase 3 trial for knee osteoarthritis treatment. However, volatility remains high with significant insider selling observed recently.